局限期前列腺癌治疗后肿瘤学结局与治疗前磁共振表现的关联
该回顾性队列纳入3406例术前行前列腺磁共振并接受根治性前列腺切除或放疗的局限期前列腺癌患者,按T2WI表现分为四级,中位随访10.8年。结果示磁共振分级越高,转移和前列腺癌死亡风险越高,且独立于EAU风险分组、CAPRA评分和治疗方式;磁共振与临床指标联合可显著提高预后准确性。
要点
- 治疗前T2WI磁共振表现分级与转移和前列腺癌死亡风险独立相关。
- 磁共振联合EAU或CAPRA评分可提高转移和前列腺癌死亡的预后判别。
- 磁共振表现可为局限期前列腺癌个体化治疗决策提供额外信息。
核心结论
- 局限期前列腺癌的治疗前磁共振表现与长期转移和前列腺癌死亡相关。
- 磁共振与临床病理数据联合可更准确地进行预后判断。
研究设计与样本
- 回顾性队列研究,纳入2001至2006年间术前接受前列腺磁共振、随后行前列腺切除(2160例)或放疗(1246例)的连续3406例男性。
- 磁共振T2WI图像回顾性判读并分为四级:无局灶可疑病灶、器官局限局灶病灶、伴前列腺外侵犯的局灶病灶、伴精囊侵犯的局灶病灶。
- 记录基于EAU指南的临床风险和CAPRA评分,采用Cox模型和逆概率删失加权估计生存概率与c指数。
主要发现
- 中位随访10.8年(IQR 8.6-13.0)。
- 磁共振分级越高,发生转移的可能性越高(HR 3.5-18.1,所有磁共振分类p<0.001)。
- 磁共振分级越高,前列腺癌死亡风险越高(HR 3.1-29.7,p<0.001-0.025)。
- 上述关联独立于EAU风险分类、CAPRA评分和治疗方式(手术 vs 放疗)。
- 联合磁共振后转移预后c指数提高:EAU 0.798 vs EAU+MRI 0.872;CAPRA 0.808 vs CAPRA+MRI 0.877。
关键数值与推荐
- 磁共振T2WI表现分为四级:I无局灶可疑病灶、II器官局限局灶病灶、III伴前列腺外侵犯的局灶病灶、IV伴精囊侵犯的局灶病灶。
- 临床风险采用EAU指南和CAPRA评分系统记录。
临床怎么用
- 在局限期前列腺癌治疗前,可将磁共振T2WI表现分级与EAU或CAPRA评分联合用于预后评估。
- 磁共振表现有助于识别转移和前列腺癌死亡风险更高的患者,辅助个体化管理。
局限性
- 磁共振图像为回顾性判读。
- 研究为单队列回顾性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We investigated whether T2-weighted magnetic resonance imaging findings could improve upon established prognostic indicators of metastatic disease and prostate cancer specific survival. MATERIALS AND METHODS: For a cohort of 3,406 consecutive men who underwent prostate magnetic resonance imaging before prostatectomy (2,160) or radiotherapy (1,246) between 2001 and 2006, T2-weighted magnetic resonance imaging exams were retrospectively interpreted and categorized as I) no focal suspicious lesion, II) organ confined focal lesion, III) focal lesion with extraprostatic extension or IV) focal lesion with seminal vesicle invasion. Clinical risk was recorded based on European Association of Urology (EAU) guidelines and the Cancer of the Prostate Risk Assessment (CAPRA) scoring system. Survival probabilities and c-indices were estimated using Cox models and inverse probability censoring weights, respectively. RESULTS: The median followup was 10.8 years (IQR 8.6-13.0). Higher magnetic resonance imaging categories were associated with a higher likelihood of developing metastases (HR 3.5-18.1, p <0.001 for all magnetic resonance imaging categories) and prostate cancer death (HR 3.1-29.7, p <0.001-0.025); these associations were statistically independent of EAU risk categories, CAPRA scores and treatment type (surgery vs radiation). Combining EAU risk or CAPRA scores with magnetic resonance imaging categories significantly improved prognostication of metastases (c-indices: EAU: 0.798, EAU + magnetic resonance imaging: 0.872; CAPRA: 0.808, CAPRA + magnetic resonance imaging: 0.877) and prostate cancer death (c-indices: EAU 0.813, EAU + magnetic resonance imaging: 0.889; CAPRA: 0.814, CAPRA + magnetic resonance imaging: 0.892; p <0.001 for all). CONCLUSION: Magnetic resonance imaging findings of localized prostate cancer are associated with clinically relevant long-term oncologic outcomes. Combining magnetic resonance imaging and clinicopathological data results in more accurate prognostication, which could facilitate individualized patient management.
引用
- Wibmer AG, Chaim J, Lakhman Y, et al. Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic Resonance Imaging Findings. J Urol. 2020. PMID: 33207133. doi:10.1097/JU.0000000000001474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。